Kidney cancer care improves with vaccine-based approach

The Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute has opened a novel Phase III, vaccine-based clinical trial aimed at providing kidney cancer patients long-term control of their disease.

Survival outcomes for patients with , the most common form of , have improved significantly over the past decade due to research advances in personalized or "targeted" therapies designed to target an individual's genetic makeup. To expedite these benefits, investigators are now looking to couple targeted therapies with vaccine-based approaches, which use a patient's own immune system to fight disease and may have the potential to improve and overall quality of life.

In "Ask the Author: Drug Evaluation," an article published in the journal Immunotherapy, Robert Figlin, MD, deputy director of the Samuel Oschin Comprehensive Cancer Institute and global principal investigator of the Phase III clinical trial, explains that combining targeted therapies with a vaccine-based approach may revolutionize the treatment of renal cell carcinoma through the next decade.

"Translational research efforts in advanced renal cell carcinoma are providing the best hope and the strongest outcomes for patients," said Figlin, the Steven Spielberg Family Chair in Hematology Oncology. "With innovative thinking and treatment approaches, and learning from past progress, we are paving the way for promising research advancements and improved patient care."

To further test the outcomes of combining a vaccine-based approach with targeted therapies, Cedars-Sinai is enrolling patients in the clinical trial using an investigational vaccine known as AGS-003. This trial acts in combination with the targeted therapy Sunitinib to maximize an immune response in , with a goal of adding little to no toxicity.

"This clinical trial asks one of the most important questions facing the field of kidney cancer at this time: Is there synergy between immunotherapy and targeted agents?" said Edwin Posadas, MD, co-investigator of the clinical trial, medical director of the Urologic Oncology Program at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute and associate professor in the Department of Medicine. "This study could be the first of many to truly redefine the approach investigators take to treat kidney cancer in the clinic."

More information: Immunotherapy. 2013 December: A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.

Related Stories

Novel study charts aggressive prostate cancer

date Nov 18, 2013

Many patients diagnosed with prostate cancer have indolent, slow-growing forms of the disease that are not life-threatening. However, more than 30,000 American men will die from aggressive prostate cancer this year alone. ...

Recommended for you

DNA blood test detects lung cancer mutations

date Apr 17, 2015

Cancer DNA circulating in the bloodstream of lung cancer patients can provide doctors with vital mutation information that can help optimise treatment when tumour tissue is not available, an international group of researchers ...

Tumors prefer the easy way out

date Apr 17, 2015

Tumor cells become lethal when they spread. Blocking this process can be a powerful way to stop cancer. Historically, scientists thought that tumor cells migrated by brute force, actively pushing through whatever ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.